In 2024, China National Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, China National Medicines has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 907a |
Total Scope 2 | |
Unspecified Calculation Method | 24,918a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.1308a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of China National Medicines amounted to 25,825 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of China National Medicines were 907 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, China National Medicines reported Scope 2 greenhouse gas (GHG) emissions of 24,918 tCO₂e without specifying the calculation method.a
In 2024, China National Medicines reported its Scope 2 emissions using an unspecified methodology.a
In 2024, China National Medicines reported Scope 1 greenhouse gas (GHG) emissions of 907 tCO₂e and total revenues of USD 6,934 millions. This translates into an emissions intensity of 0.13 tCO₂e per millions USD.a
In 2024, China National Medicines reported a Scope 1 emissions intensity of 0.13 tCO₂e per millions USD. Compared to the peer group median of 1.04, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, China National Medicines ranked 2 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places China National Medicines among the top performers, with one of the lowest emissions intensities relative to peers.a